Phase 3 trial for Moderna COVID-19 vaccine begins amid US summer surge

Today marks the start of the phase 3 trial of Moderna’s COVID-19 vaccine candidate. The COVE trial (Coronavirus Efficacy) will enroll 30,000 people at 89 sites across the country, with half the recipients receiving two shots of the vaccine […]

Click here to view original web page at Phase 3 trial for Moderna COVID-19 vaccine begins amid US summer surge

Late-stage coronavirus vaccine trial starts today in the US

The first large phase 3 trial of a candidate coronavirus vaccine in the U.S. began today (July 27). The biotech company Moderna is conducting the phase 3 trial, called COVE (Coronavirus Efficacy), in collaboration with the National Institute of […]

Click here to view original web page at Late-stage coronavirus vaccine trial starts today in the US

Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

Abstract Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant […]

Click here to view original web page at Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and […]

Click here to view original web page at Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics

The First Coronavirus Vaccine Tested in Humans Shows Early Promise

Ted S. Warren/Associated Press An experimental coronavirus vaccine made by the biotech company Moderna provoked a promising immune response against the virus and appeared safe in the first 45 people who received it, researchers reported on Tuesday in The […]

Click here to view original web page at The First Coronavirus Vaccine Tested in Humans Shows Early Promise

Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus

SARS-CoV-2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 and subsequent priming by TMPRRS2 allowing membrane fusion. Here, we produced extracellular vesicles (EVs) exposing ACE2 and demonstrate that ACE2-EVs are efficient decoys […]

Click here to view original web page at Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus

In vivo structural characterization of the whole SARS-CoV-2 RNA genome identifies host cell target proteins vulnerable to re-purposed drugs

SARS-CoV-2 is an RNA virus of the Coronaviridae family that is the causal pathogen of the ongoing Coronavirus Disease 2019 pandemic. There are currently no antiviral drugs or vaccines to treat COVID-19, and the failure to identify effective interventions […]

Click here to view original web page at In vivo structural characterization of the whole SARS-CoV-2 RNA genome identifies host cell target proteins vulnerable to re-purposed drugs